Zanubrutinib is primarily used in the treatment of certain types of blood cancers, particularly B-cell malignancies. It is specifically effective in managing conditions like mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM). The drug works by inhibiting Bruton’s tyrosine kinase (BTK), a key enzyme involved in the growth and survival of cancer cells in these diseases. This targeted approach helps to slow down or stop the progression of the cancer, improving patient outcomes. Zanubrutinib is often prescribed for patients who have not responded well to other treatments or for those who require a more targeted therapy option. Its ability to selectively block BTK with minimal off-target effects makes it a valuable option in the oncology field.